Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCell InstituteTSE:7096 -0.39%67 EV-to-EBITDA is 15.08 as of Sep. 05, 2026, which is 68% below its 10-year median of 47.20. GuruFocus rates TSE:7096 with a GF Score™ of 67/100 and a GF Value™ of 円1,842.19 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 403 Biotechnology companies, StemCell Institute ranks worse than 51.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, StemCell Institute's enterprise value is 円5,420 Mil.
StemCell Institute's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円359 Mil. Therefore, StemCell Institute's EV-to-EBITDA for today is 15.08.
The historical rank and industry rank for StemCell Institute's EV-to-EBITDA or its related term are showing as below:
TSE:7096'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.31 Med: 47.2 Max: 309.6
Current: 15.08
During the past 9 years, the highest EV-to-EBITDA of StemCell Institute was 309.60. The lowest was 11.31. And the median was 47.20.
TSE:7096's EV-to-EBITDA is ranked worse than 51.86% of 403
companies
in the Biotechnology industry
Industry Median: 13.7
vs TSE:7096: 15.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
StemCell Institute (TSE:7096) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
StemCell Institute's PE Ratio (TTM) for today is calculated as:
StemCell Institute's share price for today is 円761.00.
StemCell Institute's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円14.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for StemCell Institute's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7096 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, StemCell Institute's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where StemCell Institute's EV-to-EBITDA falls into.
StemCell Institute's current Enterprise Value is 円5,420 Mil.
StemCell Institute's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円359 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCell Institute (TSE:7096) has a EV-to-EBITDA of 15.08 as of Sep. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on StemCell Institute. This is 68% below median its historical median of 47.20. Over the past decade, StemCell Institute's EV-to-EBITDA has ranged from 11.31 to 309.60. According to the industry distribution chart, StemCell Institute ranks #209 out of 403 companies in the Biotechnology industry, placing it in the top 51.9%.
Is StemCell Institute's EV-to-EBITDA too high?
StemCell Institute's current EV-to-EBITDA of 15.08 is 68% below median its 10-year median of 47.20. Over the past 10 years, this metric has ranged from a low of 11.31 to a high of 309.60. The Biotechnology industry median EV-to-EBITDA is 13.70. StemCell Institute's value of 15.08 is 10.1% above this industry median. Based on the distribution chart, StemCell Institute ranks #209 out of 403 companies in the Biotechnology industry, which is below the industry midpoint. Overall, StemCell Institute has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #209 out of 403 companies for EV-to-EBITDA. This places StemCell Institute in the lower half of its industry. The industry median EV-to-EBITDA is 13.70. StemCell Institute's value of 15.08 is 10.1% above this benchmark. Historically, StemCell Institute's own EV-to-EBITDA has ranged from 11.31 to 309.60 over the past decade. While the company's 10-year median is 47.20 vs. the industry median of 13.70, StemCell Institute has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCell Institute's current EV-to-EBITDA of 15.08 is 10.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on StemCell Institute. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCell Institute's current EV-to-EBITDA is 15.08, which is 68% below median its own 10-year median of 47.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,842.19, compared to a current price of 円761.00 — trading 58.7% below its estimated fair value. The current EV-to-EBITDA is 15.08, which is 68% below median its 10-year median of 47.20 and 10.1% above the Biotechnology industry median of 13.70. StemCell Institute's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current EV-to-EBITDA is 15.08 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円761.00 is trading 58.7% below its estimated GF Value™ of 円1,842.19.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
EV-to-EBITDA: 15.08 (68% below median its 10-year median of 47.20)
GF Value™: 円1,842.19 vs. price of 円761.00 (58.7% below fair value)
Industry Position: 10.1% above the Biotechnology median (#209 of 403)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
67GF Score
Get the complete analysis for TSE:7096
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
